Quotient Sciences Deploys AI Formulation Platform for Acesion Pharma Atrial Fibrillation Pipeline
- Quotient Sciences will apply machine learning and Bayesian optimization to accelerate oral formulation development for Acesion Pharma's early-stage small-molecule atrial fibrillation candidates.
- The AI-enhanced solution integrates within Quotient's Translational Pharmaceutics® platform to predict formulation performance earlier and shorten development timelines.
Operational Impact
Quotient Sciences' AI formulation platform demonstrates a competitive differentiation in translational pharmaceutics that may influence CRO vendor selection for biotech sponsors seeking faster formulation decision-making and earlier clinical readiness.
Source: PharmaSource RSS